等待开盘 02-02 09:30:00 美东时间
0.000
0.00%
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC Cardiff Oncology Inc. announced positive interim results from its randomized Phase 2 clinical trial (CRDF-004) evaluating onvansertib in combination with standard of care regimens (FOLFIRI/bevacizumab or
01-28 01:11